- 1 payment so far since Mar 24 totalling 0.2500 THB/unit
- Not guaranteed Dividends are paid from the fund's profit and may be reduced or suspended
THB/unit, totalled by year of payment · * 2026 to 13 Nov 2026
SCBGHCP invests in the master fund Janus Henderson Global Life Sciences Fund (Ireland). Actual total expense ratio (TER) 0.10% a year. Pays no dividends. Data as of 13 Nov 2026.
SCB GLOBAL HEALTH CARE EQUITY FUND
Shows where this fund stands in its group. Not investment advice
SCBGHCP invests through the master fund Janus Henderson Global Life Sciences Fund
This fund and the master fund each charge their own fees. See the fees section of this page for the actual fees
Data as of 31 Oct 2026 · Top 6 shown, the rest grouped as Other · per Janus Henderson fact sheet
No AIMC group to compare with
| Return | SD | MDD | Return/SD | |
|---|---|---|---|---|
| YTD | −3.80% | −17.63% | ||
| 1D | −0.65% | −0.65% | ||
| 1W | +1.48% | −1.70% | ||
| 2W | +1.48% | −3.20% | ||
| 1M | +8.15% | −3.20% | ||
| 3M | −1.73% | −14.01% | ||
| 6M | +8.58% | −14.01% | ||
| 1Y | +0.29% | 20.56% | −17.63% | +0.01 |
| 3Y | +26.43%+8.13%/yr | 17.49% | −23.57% | +0.47 |
| 5Y | +1.10%+0.22%/yr | 17.60% | −23.57% | +0.01 |
| 7Y | +27.04%+3.48%/yr | 19.49% | −29.54% | +0.18 |
| MAX | +32.26%+3.55%/yr | 19.14% | −29.54% | +0.19 |
| Return | MDD | SD | Return/SD | |
|---|---|---|---|---|
| YTD | −3.80% | −17.63% | ||
| 1D | −0.65% | −0.65% | ||
| 1W | +1.48% | −1.70% |
Past performance is not a guarantee of future results
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Full year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −0.1 | +1.7 | −14.2 | +1.1 | +1.0 | +9.3 | −2.0 | +3.0 |
Largest drawdown in the selected period −29.54% Previous peak 12 Feb 2020 (NAV 11.1988) → Trough 23 Mar 2020 (NAV 7.8908) · Back to the previous peak on 15 Jul 2020, after 3 months
Currently −6.11% from the peak NAV of 13.7263 (22 Jan 2026)
No dividends paid in the past 12 months
SCBGHCP pays cash dividends to unitholders from part of the fund's profit. Below is a summary of when you get paid, how much, and how regularly
THB/unit, totalled by year of payment · * 2026 to 13 Nov 2026
It is an equity fund.
Risk level 7 of 8 (High risk). Since 9 Nov 2018, its NAV has fallen as much as −29.54% from its peak.
Actual total expense ratio (TER) 0.10% a year, against a ceiling of 1.82%. Management fee 0.00%. Front-end fee 0.00%. Back-end fee 0.00%. (Fact sheet 30 Sep 2026)
No. Gains or losses accumulate in the NAV, and investors receive their return when they redeem units
Minimum first purchase not set, subsequent purchases not set. Buy orders accepted until N/A, sell orders until N/A
Warning Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision
Diabetes and weight-loss drugs
An American medicines and medical devices company, with products such as cancer drugs and surgical instruments
Hospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
Weights within the master fund itself. How much of this fund's value is in the master fund is not yet known · stocks as of 31 Oct 2026 · fact sheet from Janus Henderson · Illustrations are for explanation only, not individual stock recommendations
| 2W | +1.48% | −3.20% |
| 1M | +8.15% | −3.20% |
| 3M | −1.73% | −14.01% |
| 6M | +8.58% | −14.01% |
| 1Y | +0.29% | −17.63% | 20.56% | +0.01 |
| 3Y | +26.43%+8.13%/yr | −23.57% | 17.49% | +0.47 |
| 5Y | +1.10%+0.22%/yr | −23.57% | 17.60% | +0.01 |
| 7Y | +27.04%+3.48%/yr | −29.54% | 19.49% | +0.18 |
| MAX | +32.26%+3.55%/yr | −29.54% | 19.14% | +0.19 |
| −9.4 |
| +6.6 |
| +1.5 |
| · |
| −3.8* |
| 2025 | +5.3 | +0.2 | −4.8 | −0.9 | −5.9 | +2.0 | −1.0 | +5.9 | +1.8 | +8.9 | +9.1 | −0.4 | +20.3 |
|---|
| 2024 | +2.3 | +3.9 | +2.0 | −5.1 | +3.1 | +3.2 | +1.3 | +3.7 | −4.7 | −3.7 | −0.3 | −7.5 | −2.6 |
|---|
| 2023 | −0.0 | −6.8 | −0.2 | +3.5 | −2.6 | +2.5 | +0.1 | −1.8 | −5.3 | −7.0 | +6.7 | +7.0 | −5.0 |
|---|
| 2022 | −9.3 | +0.3 | +3.4 | −6.7 | −1.0 | −1.0 | +4.3 | −3.3 | −3.0 | +8.4 | +5.0 | −1.3 | −5.5 |
|---|
| Average | +0.4 | −0.5 | −3.7 | +0.5 | −0.6 | +3.8 | +0.5 | +1.4 | −3.8 | +2.6 | +3.7 | +0.3 | +7.0 |
|---|